Renal Complications in COVID-19 Described
Patients hospitalized with COVID-19 who have preexisting kidney conditions are more susceptible to renal complications, a new systematic review and meta-analysis suggest.
Hyperkalemia
Potassium Binder May Increase Sodium Bicarbonate in CKD
In 3 trials of sodium zirconium cyclosilicate, serum bicarbonate increased regardless of CKD stage.
Patiromer Enables Spironolactone Use in Advanced CKD With Heart Failure
According to a new analysis of the AMBER study, more heart failure patients treated with patiromer than placebo remained on spironolactone therapy at 12 weeks.
Hyperkalemia Recurrence Risk Rises Along With Number of Episodes
The risk of hyperkalemia recurrence in patients with chronic kidney disease increases for each hyperkalemia episode a person experiences.
Post-Hyperkalemia Continuation of MRAs Linked to Lower Cardiovascular Risks
Patients with heart failure who remained on mineralocorticoid receptor antagonists after a hyperkalemia episode had a lower risk for major cardiovascular events than those who stopped taking the medications, a study found.
Potassium Binders Appear Effective for Hyperkalemia in Transplant Recipients
In 2 small case series of solid-organ transplant recipients, the potassium binders patiromer and sodium zirconium cyclosilicate appeared effective in the short term in managing hyperkalemia.
Plant-Based Diet Not Associated With Serious Hyperkalemia in CKD
Personalized nutritional counseling appears essential in maintaining a low-protein diet.
Hyperkalemia Management Varies in the US
No dominant treatment strategy was observed among 11 nephrology practices across the United States.
RAAS Discontinuation in Pediatric Advanced CKD Leads to Kidney Function Decline
In a propensity score-matched analysis, children who discontinued renin-angiotensin-aldosterone system inhibition (RAASi) had significantly faster eGFR decline compared with those who continued RAASi.
Potassium Binder Dosing Regimen for HD Patients Receives FDA Approval
In its first label update since sodium zirconium cyclosilicate was approved in 2018, FDA has a dosage regimen specifically to treat hyperkalemia in stable hemodialysis patients.
-
Loading...
-
Loading...
Next post in Hyperkalemia
